Literature DB >> 32888071

A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer.

Nan Meng1,2, Xuejia Wang3, Jing Sun4, Dongming Han3, Yan Bai1,2, Wei Wei1,2, Zhe Wang5, Fei Jia3, Kaiyu Wang6, Meiyun Wang7,8.   

Abstract

OBJECTIVES: To compare the value of amide proton transfer-weighted imaging (APTWI) and diffusion kurtosis imaging (DKI) in differentiating benign and malignant breast lesions and analyze the correlations between the derived parameters and prognostic factors of breast cancer.
METHODS: One hundred thirty-five women underwent breast APTWI and DKI. The magnetization transfer ratio asymmetry (MTRasym (3.5 ppm)), apparent kurtosis coefficient (Kapp), and non-Gaussian diffusion coefficient (Dapp) were calculated according to the histological subtype, grade, and prognostic factors (Ki-67, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), lymph node metastasis, and maximum lesion diameter). The differences, efficacy, and correlation between the parameters were determined.
RESULTS: The Kapp value was higher and the Dapp and MTRasym (3.5 ppm) values were lower in the malignant group than in the benign group (all p < 0.001; AUC (Kapp) = 0.913, AUC (Dapp) = 0.910, and AUC (MTRasym (3.5 ppm)) = 0.796). The differences in the AUC between Kapp and MTRasym (3.5 ppm) and between Dapp and MTRasym (3.5 ppm) were significant (p = 0.023, 0.046). Kapp was moderately correlated with the pathological grade (|r| = 0.724) and mildly correlated with Ki-67 and HER-2 expression (|r| = 0.454, 0.333). Dapp was moderately correlated with the pathological grade (|r| = 0.648) and mildly correlated with Ki-67 expression (|r| = 0.400). MTRasym (3.5 ppm) was only mildly correlated with the pathological grade (|r| = 0.468).
CONCLUSION: DKI is superior to APTWI in differentiating between benign and malignant breast lesions. Each parameter is correlated with some prognostic factors to a certain extent. KEY POINTS: • DKI and APTWI provide valuable information regarding lesion characterization. • Kapp, Dapp, and MTRasym (3.5 ppm) are valid parameters for the characterization of tissue microstructure. • DKI is superior to APTWI in the study of breast cancer.

Entities:  

Keywords:  APT; Breast neoplasms; Diffusion magnetic resonance imaging

Mesh:

Substances:

Year:  2020        PMID: 32888071     DOI: 10.1007/s00330-020-07169-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  5 in total

1.  A Nomogram Based on Molecular Biomarkers and Radiomics to Predict Lymph Node Metastasis in Breast Cancer.

Authors:  Xiaoming Qiu; Yufei Fu; Yu Ye; Zhen Wang; Changjian Cao
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

2.  A Comparative Assessment of MR BI-RADS 4 Breast Lesions With Kaiser Score and Apparent Diffusion Coefficient Value.

Authors:  Lingsong Meng; Xin Zhao; Lin Lu; Qingna Xing; Kaiyu Wang; Yafei Guo; Honglei Shang; Yan Chen; Mengyue Huang; Yongbing Sun; Xiaoan Zhang
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

3.  Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer.

Authors:  Chunping Mao; Wei Jiang; Jiayi Huang; Mengzhu Wang; Xu Yan; Zehong Yang; Dongye Wang; Xiang Zhang; Jun Shen
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

4.  Prediction of Prognostic Factors and Genotypes in Patients With Breast Cancer Using Multiple Mathematical Models of MR Diffusion Imaging.

Authors:  Weiwei Wang; Xindong Zhang; Laimin Zhu; Yueqin Chen; Weiqiang Dou; Fan Zhao; Zhe Zhou; Zhanguo Sun
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

Review 5.  Diffusion Breast MRI: Current Standard and Emerging Techniques.

Authors:  Ashley M Mendez; Lauren K Fang; Claire H Meriwether; Summer J Batasin; Stéphane Loubrie; Ana E Rodríguez-Soto; Rebecca A Rakow-Penner
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.